YIBAI PHARMACEUTICAL received the "Notice of Suspension of Production and Sales" from the Guizhou Provincial Drug Administration
YIBAI PHARMACEUTICAL received a "Notice of Suspension of Production and Sales" from the Guizhou Provincial Drug Administration, due to the discovery of defects during inspection, requiring an immediate suspension of the production and sales of the children's cough syrup. The revenue contribution of this product from 2021 to 2024 is relatively small, and it is expected that this suspension will not have a significant impact on the company's performance
According to the Zhitong Finance APP, YIBAI PHARMACEUTICAL (600594.SH) announced that it recently received a "Notice of Suspension of Production and Sales" issued by the Guizhou Provincial Drug Administration (Qian Yao Jian Sheng Chan [2025] No. 4).
- Main content of the "Notice of Suspension of Production and Sales"
Guizhou Yibai Pharmaceutical Co., Ltd.: During the inspection conducted by the National Medical Products Administration's Food and Drug Review and Inspection Center, it was found that your company has defects, involving individual records that were not filled out truthfully, and some electronic data that were not recorded in a reliable manner. After comprehensive evaluation by the National Medical Products Administration's Verification Center, the conclusion is non-compliance. According to the requirements of the National Medical Products Administration's Drug Regulatory Department in the "Notice on Investigation and Handling of Issues Related to Guizhou Yibai Pharmaceutical Co., Ltd." (Yao Jian Yao Guan Han [2025] No. 277), combined with the circumstances of suspension of production and sales in Article 7 of the "Implementation Rules for Risk Control Measures for Drug Safety Hazards of Guizhou Provincial Drug Administration," and in accordance with Article 61 of the "Drug Inspection Management Measures (Trial)," you are hereby notified to immediately suspend the production and sales of children's cough syrup upon receipt of this notice.
- Impact on the company and risk warning
The company's product, children's cough syrup, generated operating revenues of 3.42 million yuan, 4.32 million yuan, 8.38 million yuan, and 1.51 million yuan in 2021, 2022, 2023, and 2024, respectively, accounting for 0.10%, 0.16%, 0.30%, and 0.07% of the company's consolidated revenue during the same period, indicating a relatively small proportion of revenue. The suspension of production and sales of children's cough syrup is expected not to have a significant impact on the company's performance
